Tuck,
Don't know what the resident gurus think of ASTM (http://www.aastrom.com/), but with today's approval of expanded stem cell research in the UK along with EU approval to sell their system, perhaps it can be added to the taxonomy, if not the portfolio.
Regards
SMH
-----------
Britain's parliament members voted to extend its 1990 Human Fertilisation and Embryology Act to allow stem cells to be used for research into non-congenital diseases. The 1990 Act had allowed research using human embryos only for purposes related to infertility, and for a limited period of 14 days.
------------
Aastrom Biosciences, Inc. is pioneering the development of proprietary clinical systems including the AastromReplicell(TM) System, a first of its kind product, to enable physicians and patients greater accessibility to cells used for therapy. The AastromReplicell(TM) System product line consists of an instrumentation platform that can operate a growing number of patient-specific therapy kits tailored to each cell therapy application. This product platform is intended to provide a standardized and automated way of producing cells that comply with the necessary regulatory standards, ultimately making cells more readily available in medical practice. Aastrom has received patents covering methods and devices for the ex vivo production of human stem cells, as well as for the genetic modification of stem cells. The AastromReplicell(TM) System has received CE Mark approval, necessary for European marketing. The product is not available for sale at this time in the U.S., except for research or investigational use. |
